Celltrion, Inc.

In the news

Coronavirus: Week of July 12 to July 18, Australian PM seeks to delay parliament Jul 18, 2020
Glove makers and net stocks see COVID-19 boom in bear market Jul 1, 2020
SK Biopharm highlights drugs pipeline ahead of planned $800m IPO Jun 15, 2020
Takeda sells 18 drugs to South Korea's Celltrion in $278m deal Jun 12, 2020
Celltrion's coronavirus drug shows promise in animal tests Jun 1, 2020

Company Background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

Business Summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2019	KRW	USD
Revenue	1,128.45B	967.65M
Gross Profit	623,222.91M	534.41M
Operating income	378,062.36M	324.18M
Income before tax	374,013.70M	320.71M
Net income	297,556.85M	255.15M
EBITDA	537,282.22M	460.71M
Diluted EPS	2,218.68	1.90
Dividends Per Share	0	0
Total Assets	3,893.69B	3,366.93M
Total liabilities	986,733.41M	853.24M
Total equity	2,794.15B	2,416.14M
Operating cash flow	468,031.66M	401.33M
	Currency in KRW	Currency in USD

Historical Data

KRW | USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019
Revenue	603,412.76M	670,580.96M	949,079.96M	982,074.95M	1,128.45B
Gross Profit	361,042.87M	388,407.95M	685,318.99M	541,284.44M	623,222.91M
Operating income	258,922.92M	249,614.31M	507,771.41M	338,291.33M	378,062.36M
Income before tax	162,901.39M	228,752.75M	491,503.19M	317,725.82M	374,013.70M
Net income	154,089.61M	177,994.50M	382,467.03M	261,841.76M	297,556.85M
EBITDA	341,097.00M	338,289.64M	605,721.68M	465,057.52M	537,282.22M
Diluted EPS	1,187.40	1,330.99	2,794.58	1,943.56	2,218.68
Dividends Per Share	0	0	0	0	0
Total Assets	2,825.98B	3,117.56B	3,410.79B	3,628.33B	3,893.69B
Total liabilities	1,015.16B	914,607.61M	975,863.55M	992,561.59M	986,733.41M
Total equity	1,694.23B	2,053.63B	2,308.89B	2,524.02B	2,794.15B
Operating cash flow	45,199.75M	230,062.47M	482,870.20M	372,074.18M	468,031.66M

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019
Revenue	533.14M	577.99M	839.51M	892.37M	967.65M
Gross Profit	318.99M	334.77M	606.20M	491.84M	534.41M
Operating income	228.77M	215.14M	449.15M	307.39M	324.18M
Income before tax	143.93M	197.16M	434.76M	288.70M	320.71M
Net income	136.14M	153.41M	338.31M	237.92M	255.15M
EBITDA	301.37M	291.58M	535.79M	422.58M	460.71M
Diluted EPS	1.04	1.14	2.47	1.76	1.90
Dividends Per Share	0	0	0	0	0
Total Assets	2,410.12M	2,581.19M	3,186.01M	3,251.78M	3,366.93M
Total liabilities	865.77M	757.25M	911.55M	889.55M	853.24M
Total equity	1,444.91M	1,700.31M	2,156.73M	2,262.07M	2,416.14M
Operating cash flow	39.93M	198.29M	427.12M	338.09M	401.33M

Valuation Measures

Dec 2019
PER	81.17
ROA	7.91%
ROE	11.19%
Operating margin	33.50%
Profit margin	26.36%

Key executives

Chief Executive Officer & Director: Wu-Sung Ki
Finance Director: Ho-Seop Lee
Head-Legal & Compliance Support: Sung-Han Lee
Vice President: Sang-Joon Lee
Vice President: Jung-Won Yoon

Shareholders

SEO JUNG-JIN (22.1%)
National Pension Service of Korea (9.1%)
Temasek Holdings Pte Ltd. (Investment Management) (7.4%)
The Vanguard Group, Inc. (2.1%)
BlackRock Fund Advisors (1.5%)
Celltrion, Inc. (0.8%)
Norges Bank Investment Management (0.8%)
Mirae Asset Global Investments Co., Ltd. (0.7%)
Celltrion Inc. Employee Stock Ownership ASSN. (0.5%)
BlackRock Advisors (UK) Ltd. (0.4%)

Contact Details

Website:http://www.celltrion.com
Address: 23 Academy-ro, Yeonsu-gu, Inchon, 22014, South Korea
Phone: +82.32.850.5000

Related Companies

Celltrion Inc. Employee Stock Ownership ASSN.
Celltrion Pharm Inc.

Competitors

Novartis AG
Pfizer Inc.
Mylan N.V.
AbbVie, Inc.
Amgen Inc.
Gilead Sciences, Inc.
Biocon Limited
Merck KGaA
SAMSUNG BIOLOGICS Co., Ltd.
EPIRUS Biopharmaceuticals, Inc.
Reyon Pharmaceutical Co., Ltd.
Wooridul Pharmaceutical Ltd.
Sinocelltech Group Limited Class A
Mabion SA
ALTEOGEN Inc.
PharmAbcine, Inc.
Dexter Studios Co., Ltd.

Last Updated on 3 Aug, 2020